Predictive Oncology Q2 EPS $(0.68) Up From $(0.98) YoY, Sales $278.72K Down From $490.11K YoY
Portfolio Pulse from Benzinga Newsdesk
Predictive Oncology (NASDAQ:POAI) reported Q2 EPS of $(0.68), an improvement from $(0.98) YoY, but sales decreased by 43.13% to $278.72K from $490.11K YoY.
August 14, 2024 | 6:43 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Predictive Oncology reported a Q2 EPS of $(0.68), an improvement from $(0.98) YoY. However, sales decreased by 43.13% to $278.72K from $490.11K YoY.
While the EPS improvement is a positive sign, the significant drop in sales is concerning. This mixed result may lead to neutral short-term price movement as investors weigh the improved EPS against the declining sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100